- Warfarin
- Heparin
- Novel Oral Anticoagulants
- Others
Anticoagulation Therapy Market size is valued at USD 24,732.3 million in 2022 and is poised to grow at a significant CAGR of 7.8% from 2023-2029. The global market provides a detailed overview of the Anticoagulation Therapy market size, and that can be segmented by drug type, by route of administration, by application, and by Distribution channel. By drug type, the Anticoagulation Therapy market growth has been segmented into Warfarin, Heparin, Novel Oral Anticoagulants, and Others. The Novel oral anticoagulants (NOACs) segment is likely to be the largest and fastest-growing segment in terms of drug type. T Novel oral anticoagulants (NOACs) are a new type of anticoagulant drug. Furthermore, these are safe as a lower frequency of excessive bleeding is recorded, are suitable to use, have no reactions to food, and have a brief half-life. Some of the NOACs comprise dabigatran, apixaban, rivaroxaban, and edoxaban. These can be used in the stoppage and cure of atrial fibrillation or myocardial infarction, pulmonary embolism, and deep vein thrombosis (DVT). Based on the Route of administration, the Anticoagulation Therapy market is segmented into Oral, Parenteral. Among these, the Oral route of administration segment is expected to have the fastest-growing market during the forecast period 2022-2028. Oral anticoagulants are expected to generate the highest market revenue during the forecast period. Oral anticoagulants are one of the most traditional and standard modes of administration of anticoagulant therapy, and they are expected to expand during the forecast period. The oral anticoagulants segment is further expected to grow as there are many prominent product launches. Due to technological advancements in anticoagulants and their influence on a considerable reduction in risk, this segment is further expected to increase the global anticoagulant market growth. Based on application, the Anticoagulation Therapy market is segmented into Therapeutic applications, Clinical Laboratory Services. Among these, the Therapeutic applications segment is expected to have the fastest-growing market during the forecast period 2022-2028. Based on the Distribution channel, the Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies. The Hospital Pharmacies segment is expected to have a significant share in 2021.
Study Period
Base Year
CAGR
Largest Market
Fastest Growing Market
The growing prevalence of arrhythmia, stroke, and blood vessel thromboembolism is anticipated to propel the market growth over the forecast years. Moreover, the increasing acceptance of NOACs and the growing number of outpatients are burgeoning the market growth over the forecast years.
The anticoagulation therapy market size was valued at USD 24,732.3 million in 2022.
The Anticoagulation therapy market has been classified into North America, Asia Pacific, Europe, Latin America, Middle East and Africa, and the rest of MEA.
The Anticoagulation therapy market key players Bristol-Myers Squibb (U.S.), Pfizer, Inc. (U.S.), Johnson & Johnson Services Inc. (U.S.), Alere, Inc. (U.S.), Abbott, Inc. (U.S.), F. Hoffmann La. Roche Ltd. (Switzerland), Baxter International, Inc. (U.S.), Portola Pharmaceuticals, Inc. (U.S.), Daiichi Sankyo Company Ltd. (Japan), Siemens AG (Germany), CoaguSense, Inc. (US)